$GH

Kalia Kumud sold $157K of GH

Kalia Kumud (Chief Information Officer) sold 1,200 shares of Guardant Health, Inc. (GH) at an average of $130.97 ($130.86–$131.08, $0.16M total) across 2 trades over 2026-06-10 to 2026-06-15.

Original reporting
SEC EDGAR · Kalia Kumud
Published Jun 30, 2026, 9:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 9:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest information is the specific open-market sale details (shares, price range, total value, and post-transaction holdings) filed on 2026-06-30 for trades executed mid-June.

02

Market read

This provides a fresh datapoint on insider behavior, but it is not accompanied by guidance, earnings, or operational developments.

03

What to watch

No 10b5-1 plan is stated; traders may still treat the absence of a plan as marginally more informative, but the disclosed size remains small.

Relevance 4/10Novelty 6/10Timing: Filed after-hours on 2026-06-30; reflects sales executed 2026-06-10 to 2026-06-15.

Background

The article is a SEC Form 4 insider transaction disclosure for Guardant Health, Inc. (GH).

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health CIO Kalia Kumud filed an open-market sale of 1,200 shares at ~$130.97 (total ~$157k) on June 10–15, 2026.

Expected impact

Low likelihood of a sustained price move; any impact would be short-lived unless accompanied by other company-specific news.

Evidence & confidence

This is a Form 4 insider transaction with modest dollar value and no 10b5-1 plan stated; the filing itself is new, but it does not disclose new operating/financial information.

Market effects

Minimal; insider selling at a single healthcare/diagnostics name typically does not reset sector expectations.

None indicated; US-listed Form 4 filing with small transaction value.

None indicated; no cross-border deal/regulatory action mentioned.

Counterpoint

The sale could be unrelated to company outlook (tax/portfolio rebalancing), especially since the filing does not indicate distress or a planned program.

Key entities

  • Guardant Health, Inc.

    US-listed company whose insider transaction was disclosed via Form 4.

  • Kalia Kumud

    Chief Information Officer who sold 1,200 shares in two open-market trades.

Related articles

$GHHighAI 9/10

Guardant Health (GH) Q2 2026 Earnings Call Transcript

Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.

$GHMedAI 8/10

New blood test to detect colon cancer clears FDA approval

The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.

$GHMedAI 8/10

Guardant Health, Inc. Q2 2026 Earnings Call Summary

Guardant Health reported 44% YoY Q2 2026 revenue growth, citing strong Oncology and Screening performance. It raised full-year 2026 revenue guidance to $1.34B-$1.36B and expects lower Shield cost per test. FDA approval of Guardant360 Liquid CDx and UnitedHealth coverage for Shield from Aug. 1, 2026 are key catalysts.

$GHHighAI 9/10

Why is Guardant Health stock surging today?

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade Investing.com -- Guardant Health stock surged 8.8% in after-hours trading after the Palo Alto-based liquid biopsy pioneer reported second-quarter 2026 results that significantly exceeded revenue expectations, with sales reaching $335 million — a 44% year-over-year increase that beat the Wall Street consensus of roughly $314 million by approximately 6.4%.